A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease
- Registration Number
- NCT05068284
- Lead Sponsor
- AbbVie
- Brief Summary
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. CD may cause tiredness, loose stools with or without bleeding, abdominal pain, weight loss, and fever. This study evaluates how safe and effective ABBV-154 is in participants treated for moderately to severely active CD. Adverse events and change in the disease activity will be assessed.
ABBV-154 is an investigational drug being evaluated for the treatment of CD. In the induction period, there is a 1 in 5 chance that participants will be assigned to placebo. Depending on the dose received in the induction period, there is a 1 in 2 or 1 in 3 chance that participants will be assigned to placebo in the maintenance period. Around 265 participants 18-75 years of age with moderately to severely active CD will be enrolled in the study at approximately 200 sites worldwide.
The study is comprised of a 12-week double-blind, placebo-controlled induction period, followed by either a 12-week double-blind re-induction period for non-responders or a 40-week double-blind placebo-controlled maintenance period for responders. In the maintenance period, responders will be randomized to receive subcutaneous placebo or ABBV-154 in 2 different doses every other week. Participants in the placebo group who are initial responders will receive ABBV-154 in the maintenance period.
There may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 176
- Confirmed diagnosis of Crohn's Disease (CD) for at least 3 months prior to Baseline of the Induction Period.
- Crohn's Disease Activity Index (CDAI) score 220 to 450 at Baseline of the Induction Period.
- Endoscopic evidence of mucosal inflammation as documented by an Simple Endoscopic Score for Crohn's Disease (SES-CD) of >= 6 for ileocolonic or colonic disease or SES-CD of >= 4 for isolated ileal disease as scored by a central reader. All eligible scores must exclude the presence of narrowing component.
- Demonstrated intolerance or inadequate response to one or more of the following biologic agents: infliximab, adalimumab, certolizumab pegol, vedolizumab, natalizumab, ustekinumab, or risankizumab.
- Participants with prior intolerance to adalimumab.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Induction Phase: ABBV-154 Randomized Dose D Placebo Varying doses of ABBV-154 as described in the protocol. Induction Phase: Randomized Placebo Placebo Fixed dose placebo as described in the protocol. Maintenance Phase: Randomized Placebo Placebo Fixed dose placebo every other week. Induction Phase: ABBV-154 Randomized Dose B ABBV-154 Varying doses of ABBV-154 as described in the protocol. Induction Phase: ABBV-154 Randomized Dose C ABBV-154 Varying doses of ABBV-154 as described in the protocol. Induction Phase: ABBV-154 Randomized Dose D ABBV-154 Varying doses of ABBV-154 as described in the protocol. Re-Induction Phase: ABBV-154 Randomized Dose B ABBV-154 Varying doses of ABBV-154 as described in the protocol. Maintenance Phase: ABBV-154 Randomized Dose A ABBV-154 Fixed dose ABBV-154 every other week. Maintenance Phase: ABBV-154 Randomized Dose B ABBV-154 Fixed dose ABBV-154 every other week. Induction Phase: ABBV-154 Randomized Dose A ABBV-154 Varying doses of ABBV-154 as described in the protocol. Re-Induction Phase: ABBV-154 Randomized Dose A ABBV-154 Varying doses of ABBV-154 as described in the protocol.
- Primary Outcome Measures
Name Time Method Percentage of Participants Achieving Endoscopic Response Per Simple Endoscopic Score for Crohn's Disease (SES-CD) Baseline to Week 12 The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD \> 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline). The SES-CD evaluates 4 endoscopic variables (ulcer size, ulcerated surface, affected surface, and narrowing, each on a scale from 0 (none) to 3 (worst) in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and ranges from 0 to 56, where higher scores indicate more severe disease.
- Secondary Outcome Measures
Name Time Method Percentage of Participants Achieving Clinical Remission Per Crohn's Disease Activity Index (CDAI) Induction Period Week 12 The CDAI consists of 8 components; 6 are based on participant diary entries, participant interviews, and physical examinations, and 2 are based on laboratory analysis, and measurement of body weight and height. Clinical remission is defined as CDAI \< 150.
Percentage of Participants Achieving Clinical Remission Per Average Daily Liquid or Very Soft Stool Frequency (SF) and Average Daily Abdominal Pain (AP) Score (SF/AP) Induction Period Week 12 Clinical remission is defined as average daily liquid or very soft stool SF \<= 2.8 and not worse than Baseline and average daily AP score \<= 1 and not worse than Baseline.
Percentage of Participants Achieving Endoscopic Response Per SES-CD Week 40 in the Maintenance Period The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD \> 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).
Percentage of Participants Achieving Clinical Remission Per CDAI Week 40 in the Maintenance Period The CDAI consists of 8 components; 6 are based on participant diary entries, participant interviews, and physical examinations, and 2 are based on laboratory analysis, and measurement of body weight and height. Clinical remission is defined as CDAI \< 150.
Percentage of Participants Achieving Clinical Remission Per SF/AP Week 40 in the Maintenance Period Clinical remission is defined as average daily liquid or very soft SF \<= 2.8 and not worse than Baseline and average daily AP score \<= 1 and not worse than Baseline.
Trial Locations
- Locations (166)
Atlantic Medical Research /ID# 233506
🇺🇸Margate, Florida, United States
AGILE Clinical Research Trials /ID# 233739
🇺🇸Atlanta, Georgia, United States
Gastroenterology Consultants, P.C /ID# 233552
🇺🇸Roswell, Georgia, United States
Louisiana Research Center, LLC /ID# 245370
🇺🇸Shreveport, Louisiana, United States
Allied Health Clinical Research Organization, LLC /ID# 241935
🇺🇸Englewood, New Jersey, United States
Toronto Digestive Disease Associates, Inc. /ID# 234143
🇨🇦Vaughan, Ontario, Canada
General Hospital of Nikaia-Piraeus "Agios Panteleimon" /ID# 231659
🇬🇷Pireaus, Greece
Center hospital of the National Center for Global Health and Medicine /ID# 239792
🇯🇵Shinjuku-ku, Tokyo, Japan
2CA-Braga, Hospital de Braga /ID# 249049
🇵🇹Braga, Portugal
Digestive Health Specialists of the Southeast /ID# 239599
🇺🇸Dothan, Alabama, United States
Scroll for more (156 remaining)Atlantic Medical Research /ID# 233506🇺🇸Margate, Florida, United States